Exam 1: Things are Critical Flashcards
(199 cards)
1
Q
what is the intensive care unit?
A
-can be defined as a specialized section of a hospital that provides comprehensive care. for persons who are critically ill
–> around-the clock monitoring and treatment of critically ill patients, staffed with specially trained healthcare professionals & contains sophisticated monitoring equipment
2
Q
Pharmacist role: direct patient care activities
A
-interdisciplinary pt care rounds
-code blue/code stroke response
-perform medication histories
-prevent and manage adverse drug events/medication errors
-pharmacokinetics/pharmacodynamic monitoring
-patient and caregiver education
3
Q
Pharmacist role: indirect patient care activities
A
-policy and protocol development
-formulary management
-research
-participation in committees
4
Q
PKPD changes in critically ill patients
A
-fluid shifts
-renal dysfunction
-hepatic dysfunction
5
Q
Specific prophylaxis considerations in critically ill patients
A
-ventilator associated pneumonia
-stress ulcer prophylaxis
-venous thromboembolism prophylaxis
6
Q
Nutrition considerations in critically ill patients
A
-enteral vs parenteral
7
Q
FAST HUGS BID (what it is)
A
-emphasizes the important aspects of critical care medicine that can be applied twice daily to critically ill patients
-can serve as a “check-list” to ensure all elements of ICU care are being accounted for to provide safe, effective care in this setting
8
Q
FAST HUGS BID (what it stands for)
A
-feeding
-analgesia
-sedation
-thromboprophylaxis
-head of bed (VAP prophylaxis)
-ulcer prophylaxis
-glycemic control
-spontaneous breathing trial
-bowel regimen
-indwelling catheters
-de-escalation of antibiotics
9
Q
FAST HUGS BID: feeding
A
-malnutrition can lead to impaired immune function –> increased susceptibility to infection, impaired wound healing, bacterial overgrowth in the GI tract and an increased risk for development of decubitus ulcers
-feeding should be considered as soon as the pt is clinically stable
10
Q
FAST HUGS BID: feeding considerations
A
-emphesis on an early feeding: enteral feeding is PREFERRED –> stimulated the gut to work, has been associated with less GI bleeding
-parenteral nutrition may become necessary if the pts gut it not working or enteral feeds are not being tolerated
11
Q
FAST HUGS BID: Analgesia - why are they in pain and assessment
A
-pain due to underlying conditions (trauma, surgery), standard ICU care (lines, tubes, turning/repositioning, physical therapy )
Importance: providing adequate analgesia optimizes pt comfort and minimizes the acute stress response, hyper metabolism, increased oxygen consumption, hyper coagulability, and alterations in immune function- can also reduce the risk of developing agitation
12
Q
FAST HUGS BID: Analgesia - type of pain and common meds used
A
–> type of pain: nociceptive vs neuropathic: helps to choose best agent to relieve pain
–> duration of pain: helps us determine whether we need long acting agents or as needed boluses for situation pain
–> account for home pain regimens: make sure underdosing isnt occurring in pts that receive high doses at home
Common meds: fentanyl, hydromorphone, morphine, oxycodone
13
Q
FAST HUGS BID: Sedation
A
-pts in the ICU have multiple reasons to become agitated: anxiety, pain, lack of homeostasis, withdrawal, benzo use, sleep-wake cycle disruption
-sedative admin optimizes patient comfort and minimizes the acute stress response
14
Q
FAST HUGS BID: Sedation - assessment and drug use
A
-sedation should be assessed and reassessed with a validated tool such as RASS or SAS
-propofol and dexmedetomide are the preferred sedative agents over continuous benzos as they have been associated with more delirium and neurocognitive implications
15
Q
FAST HUGS BID: Thromboembolism Prophylaxis- importance & considerations
A
Importance: critically-ill pts have been shown to be at higher risk for VTE than general medical patients due to the additional risk factors for VTE acquired in the critical care setting
Considerations:
–> VTE prophylaxis should be given to ALL pts in the ICU
–> most common options: low molecular weight heparin (enoxaparin 40 mg SQ daily or 30 mg AQ BID) or unfractionated heparin in pts with renal dysfunction ( 500 units SQ Q8H)
-high risk pts: mechanical prophylaxis with graduated compression stockings or intermittent pneumatic compression devices should be initiated
16
Q
FAST HUGS BID: head of the bed : ventilator associated pneumonia (VAP) prophylaxis
A
-importance: specific to pts receiving mechanical ventilation: elevating the head and thorax above the bed to a 30-45 degree angle reduces the occurrence of GI reflux and nosocomial pneumonia in pts who are receiving mechanical ventilation
–> maintain the head of the bed elevated at 30-45 degrees, apply antiseptic mouthwash (chlorhexidine 0.12%) topically to the oral cavity TID to maintain pts oral hygiene to prevent bacterial growth with the endotracheal tube
17
Q
FAST HUGS BID: ulcer prophylaxis- importance
A
-critically ill pts develop stress-related mucosal damage (SRDM), potentially leading to clinically significant bleeding
(SRMD: an acute erosive, inflammatory upper GI insult to the upper GI tract associated with critical illness)
18
Q
FAST HUGS BID: ulcer prophylaxis - risk factors for GI bleeding
A
–> major (need 1): mechanical ventilation > 48 hrs or INR > 1.5, PTT > 2x ULN or platelets < 50,000
–> minor (need 2 or more): drugs that increase bleed risk (steroids, warfarin, heparin), shock/sepsis/hypotension/vasopressors, hepatic/renal failure, multiple traumas, burns > 35% total body, organ transplant, head or spinal trauma, hx of upper GI bleeding or peptic ulcer disease
Drugs to use for prophylaxis: PPIs (pantoprazole), H2RAs (famotidine) - continue until risk factors have resolved
19
Q
FAST HUGS BID: glycemic control
A
-hyperglycemia is common in critically ill pts due to meds (steroids, BBs, vasopressors), exogenous glucose (TPN)
-maintaining blood glucose at 140-180 mg/dL should be considered in the acutely ill patient
20
Q
FAST HUGS BID: Spontaneous breathing trial
A
-a spontaneous breathing trial is performed on pts on mechanical ventilation and assesses the pts ability to breathe on minimal or no ventilatory support and is designed to assess whether the pts respiratory mechanics are favorable enough to consider liberation from mechanical ventilation
–> should be performed daily to determine a pts extubation readiness with the goal of weaning off of mechanical ventilatory support as early as possible
21
Q
FAST HUGS BID: bowel regimen
A
-constipation can occur in many pts: regimen options = docusate, sennosides, polyethylene glycol for standing regimens, bisacodyl suppositories, enemas, magnesium citrate for rescue options
-diarrhea can also occur: infection, feeds, aggressive bowel regimen
22
Q
FAST HUGS BID: indwelling Catheters:
A
-important to assess lines at least daily for signs of infection
-assessing the need for these lines or if they can be removed
23
Q
peripheral venous catheters
A
a catheter placed into a peripheral vein for venous access to administer IV therapy
24
Q
centeral venous catheters
A
lines that terminate in the superior vena cava, just above the right atrium
25
arterial lines
catheters that are placed into the lumen of an artery to provide a continuous display or accurate blood pressure and access frequent arterial blood sampling
26
foley catheters
a flexible tube that passes through the urethra and into the bladder to drain urine
27
rectal tubes
a soft catheter inserted into the rectum for fecal management to contain and divert fecal waste
28
FAST HUGS BID: De-escalation of antibiotics
-broad spectrum antibiotics are common in critical care units
-applying standard antimicrobial stewardship principles should be standard of care in the critical care setting
--> de-escalating antibiotics as appropriate based on culture results
--> setting appropriate antibiotic duration to avoid under or overuse of antibiotics
--> providing necessary dose adjustments based on PK changes
29
hypertensive crisis
an acute condition of very high BP with with either SBP > 180, DBP > 120, or both
30
hypertensive urgency
pts with acute condition of very high blood pressure without evidence of new or worsening target organ damage
31
hypertensive emergency
pts with acute condition of very high blood pressure and evidence of new or worsening target organ damage
32
risk factors for HTN crisis
-female sex
-obesity
-hypertensive/coronary heart disease
-presence of a somatoform disorder
-higher number of antihypertensive agents at baseline
33
common causes of hypertensive crisis
-non-adherence with prescribed rx
-abrupt withdrawal of certain antihypertensives = rebound hypertension (clonidine, BBs)
-substance abuse (cocaine, amphetamines, ecstasy)
-drug-drug interactions (serotonin syndrome)
-drug-food interactions (tyramine containing foods with monoamine oxidase inhibitors)
-drug-disease state interactions (NSAIDs, sympathomimetics in pts with HTN)
-withdrawal (alcohol, opioids, benzos)
34
Symptoms of hypertensive crisis
-headache
-nausea
-vomiting
-epistaxis
-SOB
-chest pain
-dizziness
-paresthesia
-vision changes
35
Signs of hypertensive crisis
-focal neurological deficits
-crackles on lung auscultation
-increased Scr/BUN, LFTs
-new/worsening hematuria/proteinuria
-EKG changes
-changes on fundoycopic examination of the eye
-changes on CT of the head (bleed)
-MRI evidence of CVA
36
Management of hypertensive urgency
-lower blood pressure slowly during the first 24-48 hrs using oral medication
-no need for ICU admission
37
Management of hypertensive EMERGENCY: 1st hour
*requires IV antihypertensives and ICU admission*
-decrease DBP by 10-15% or MAP by 25% with goal DBP > 100
38
Management of hypertensive EMERGENCY: 2-6 hrs, 6-24 hrs & 24-48 hrs
2-6: SBP 160 and/or DBP 100-110
6-24: maintain above goals
24-48: gradually decrease BP to normal (outpatient goal)
39
Management of hypertensive EMERGENCY: aortic dissection
-SBP < 120 within 1st hour, HR < 60
meds: esmolol then nicardipine
40
Management of hypertensive EMERGENCY: ischemic stroke
BP < 185/110 before tPA and < 180/105 during tPA infusion
-if no tPA SBP < 220
Meds: nicardipine, clevidipine, labetalol
*avoid sodium nitroprusside*
41
Management of hypertensive EMERGENCY: hemorrhagic stroke
SBP > 220: lower with infusion and monitor
SBP 150-220: < 140 in 60 mins
Meds: clevidipine, labetalol, nicardipine
*avoid sodium nitroprusside*
42
Management of hypertensive EMERGENCY: severe Pre-eclampsia or Eclampsia
SBP < 140 in 60 mins
Meds: hydralazine, labetalol, nicardipine
*avoid RASS inhibitors and sodium nitroprusside*
43
Meds used in hypertensive emergencies: sodium nitroprusside
-onset less than 2 mins, 1-10 min duration
-AEs: hypotension (potent), N/V, muscle twitching, cyanide toxicity
-caution in pts with high intracranial pressure, azotemia, CKD
44
Meds used in hypertensive emergencies: nitroglycerin
-immediate onset, 3-5 min duration
-AEs: hypotension, headache, methemoglobinemia, tolerance with prolonged use
-most often utilized in situations with coronary ischemia
45
Meds used in hypertensive emergencies: hydralazine
*last line*
-IV bolus, 10-80 min onset and up to 12 hr duration
-AEs: hypotension, tachycardia, flushing, headache
-concern with its unpredictable PK profile
-safe for use in pregnancy
46
Meds used in hypertensive emergencies: Labetalol
-most HTN emergencies, safe to use in pregnancy, caution in acute HF
AEs: hypotension, bradycardia/heart block, orthostatic hypotension
47
Meds used in hypertensive emergencies: Metoprolol
-only given as a bolus, caution in acute HF
AEs: hypotension, bradycardia/heart block
48
Meds used in hypertensive emergencies: esmolol
-drug of choice in aortic dissection, caution use in acute HF
AEs: hypotension, bradycardia/heart block
49
Meds used in hypertensive emergencies: clevidipine
-most hypertensive emergencies, caution with coronary ischemia *CI with soy/egg allergy*
AEs: hypotension, headache, tachycardia, hypertriglyceridemia
50
Meds used in hypertensive emergencies: Nicardapine
-most hypertensive emergencies
-not generally utilized in acute HF, caution with coronary ischemia
AEs: hypotension, tachycardia, headache, flushing, local phlebitis
51
Meds used in hypertensive emergencies: enalaprilat
*rare usage*
-use in caution with acute HF, AVOID in acute MI, eclampasia, AKI
52
Meds used in hypertensive emergencies: Fenoldopam
*rare usage*
dopamine receptor agonist
-avoid in pts with glaucoma (due to increased intraoccular pressure)
AEs: hypotension, tachycardia, headache, nausea, flushing
53
DKA + HHS
both have increased concentration of catecholamines, cortisol, glucagon and growth hormone --> leads to hyperglycemia via dec in glucose utilization, inc gluconeogenesis and inc glycogenolysis
54
Precipitanting factors of DKA/HHS
-infections (UTIS and pneumonia)
-#2 myocardial infarction
-medications (steroids)
-noncompliance with therapy
-poor "sick day" management
-pancreatitis
-drug/alcohol abuse
-inadequate dose of d/c of insulin
-new onset type 1 DM
55
Clinical Presentation of DKA
-onset: hours to days
-clinical pic: kussmaul respirations, N/V, abdominal pain
-glucose: > 250
-acidosis: < 7.3
-anion gap: > 12
-ketones: positive
-serum osmolality: < 320
56
Clinical Presentation of HHS
-onset: several days to weeks
-clinical picture: neurologic manifestations (seizures, hemiparesis)
-glucose: > 600
-acidosis: normal
-anion gap: variable
-ketones: negative
-serum osmolality: > 320
57
Treatment of DKA/HHS: fluid management
-initial: 15-20 ml/kg for the first hour
Severe hypovolemia: NS @ 1 l/hr
Mild dehydration:
--> Na+ normal or high: 0.45% NaCl (250-500 ml/hr)
--> Na+ low: 0.9% NaCl (250-500 ml/hr)
Cardiogeniic shock: utilize pressors and monitor hemodynamic closely
58
Treatment of DKA/HHS: fluid management & glucose levels
-when DKA BG: 200 and HHS BG 300 change to 0.45% NaCl/D5W at 150-250 ml/hr
59
Treatment of DKA/HHS: Insulin therapy
-regular infusions are the mainstay of treatment
can do: 0.1 unit/kg as IV bolus --> 0.1 unit/kg/he infusion OR 0.14 unit/kg/hr as an IV infusion (no bolus)
-decrease infusion rate to 0.02-0.05 unitd/kg/hr when DKA < 200, HHS < 300
GOAL BG: DKA: 150-200, HHS 200-300
60
Treatment of DKA/HHS: transition from IV to SQ insulin
-when pt shows resolution of crisis & able to eat: initiate SQ basal insulin and overlap with IV infusion for 1-2 hrs
--> HX of DM with insulin: PTA dosing if it was controlling their diabetic properly (however usually started off at a decreased dose)
--> insulin naiive: multidose regimen with basal and bolus started at a dose of 0.5-0.8 units/kg/day
61
Resolutions definitions: DKA and HHS
DKA: blood glucose < 200 AND 2 of the following: serum bicarb level > 15, venous pH > 7.3, anion gap < 12
HHS: normal osmolality AND normal mental status
62
Treatment of DKA/HHS: potassium management
*check K+ before initiating insulin therapy
-K+ < 3.3: HOLD insulin and replete @ 20-30 mEq/hr until the K+ > 3.3
-K+ 3.3-5.3: 20-30 mEq K+ should be given with every L of fluid
-K+ > 5.2: do not give until it falls below the upper limit of normal
63
Treatment of DKA/HHS: bicarbonate
only indicated in pts with a pH < 6.9: 100 mmol sodium bicarb ( 2 amplules) in 400 mL of H2O + 20 mEq of Kcl over 2 hrs
-repeat q2h until pH > 7
64
Treatment of DKA/HHS: Phosphate
-insulin therapy decreases serum phosphate as it causes a shift in phosphate
-careful phosphate replacement (20-30 mEq/l potassium phosphate added to replacement fluids) is indicated in: cardiac dysfunction, anemia, respiratory depression, serum phosphate concentration < 1.0 mg/dl
65
Complications of hyperglycemia crises
-hypoglycemia: glucose should be monitored q 1-2 hrs while in insulin IV infusion
-hypokalemia: BMPs should be monitored q 4-6 hrs while insulin infusion is running
-hyperchloremic non-anion gap metabolic acidosis: secondary to excess infusion of chloride containing fluids during tx
-cerebral edema: occurs in 1-3% of DKA episodes in children, prevent by avoidance of excessive hydration and rapid reduction of plasma osmolarity. treatment: mannitol infusion and mechanical ventilation
66
Opioid treatment for analgesia: Morphine
-onset is 5-10 min, can give bolus and infusion
-active metabolites & accumulates in renal impairment --> longer duration throughout the day
AEs: histamine release: hypotension, bronchospasm, urticaria
67
Opioid treatment for analgesia: Fentanyl
-onset in seconds, with 1-2 hours duration
-hepatic metabolism, CYP3A4 interactions
-can lead to tachyphylaxis: pt developed a resistance to drug --> switch to hydromorphone
68
Opioid treatment for analgesia: hydromorphone
-5 min onset with 2-4hr duration
-good in renal impairment, option for fentanyl tolerance
-available as patient-controlled analgesia (PCA)
69
Opioid treatment for analgesia: additional options
-acetaminophen: caution in acute liver failure
-NSAID: caution in acute kidney injury, increase risk of GI bleed
-methadone: slow titration to avoid QTC prolongation
-gabapentin
-ketamine
-patient centered analgesia (PCAs)
70
Richmond agitation sedation scale (RASS)
0: calm and alert
-1: drowsy
-2: light sedation
71
Sedation agitation scale (SAS)
4: calm and co-operative
3: sedated
72
Propofol
-stimulates GABA and inhibits NMDA receptors
-has hypnotic, anxiolytic, amnestic and anticonvulsant effects
-NO analgesic properties
-duration of action: 10-15 min (rapid hepatic and extra-hepatic clearance
-long term admin can lead to saturation of peripheral tissues (highly lipid soluble)
73
Propofol AEs
-respiratory depression
-hypotension
-bradycardia
-decrease cardiac output
-hypertriglyceridemia (acute pancreatitis)
-propofol related infusion syndrome (PRIS)
74
Propofol uses and clinical pearls
-potentially 1st line agent in: severe alcohol withdrawal, status epilepticus
-lipid emulsion therefore can provide 1.1 kcal/ml of nutrition
-avoid in patients with egg, sulfites, or soybean allergies
-monitor for BP, HR, triglycerides, anoin gap/lactate and CKD when using > 48 hrs
75
Dexmedetomidine
-decreases release of norepinephrine and dopamine in CNS (alpha-2 adrenergic agonist)
-FDA approve for procedural sedation and sedation for mechanical ventilation NOT > 24 HRS
-has sedative and analgesic properties
AEs: bradycardia, hypotension
76
Dexmedetomidine benefits
-no respiratory depression
-effects are similar to naturally occurring sleep
-opioid - sparing effects
-useful as adjunct therapy for alcohol withdrawal
77
Dexmedetomidine drawbacks
-risk of hypotension
-RASS score of -3 or less is unlikely (not for someone that needs heavy sedation)
-risk of withdrawal with prolonged use
-drug induced fever?
78
Benzos used for sedation: midazolam
-2-5 min onset, 1-2 hr duration
-lipophilic, active metabolites, accumulates in renal impairment
--> primary use for status epilepticus
79
Benzos used for sedation: Lorazepam
-5-20 min onset, 2-6 hr duration
-propylene glycol acidosis
-can use in renal/hepatic failure
80
Benzos used for sedation: Diazepam
-5-10. min onset, 1/2life of 44-100 hrs
-active metabolites
-can taper off quickly
-standing doses used in alcohol withdrawal
81
Benzos used for sedation: uses & drawbacks
-reserve for first line in: status epilepticus, extreme alcohol withdrawal syndromes, severe ARDs requiring deep sedation
-drawbacks: increase risk of delirium, increase time on ventilator & increase length of ICU stay
82
Ketamine indications and MOA
-indicated for: anesthesia, pain, rapid sequence intubation, acute severe agitation, status epilepticus, treatment resistant depression & PTSD
-MOA: NMDA antagonist, Mu and Kappa agonists, muscuranic acetylcholine receptor antagonist & inhibit reuptake of serotonin, NE and dopamine
83
Ketamine dosing for pain
0.15-0.5 mg/kg/hr
84
Ketamine dosing for anesthesia
0.5-2 mg/kg/hr
85
ketamine dosing for status epilepticus
> 2 mg/kg/hr
86
Ketamine advantages & common AEs
-advantages: favorable hemodynamic, bronchodilator effects, opioid sparing effects
-AEs: emergence reaction (pretreat with benzo or propofol), oral secretions, tachycardia, hypertension
87
effects of delirium sequalae (effects of delirium)
-increase mortality
-cognitive impairment
-functional decline
-increase health system costs
-prolonged mechanical ventilation
-increase length of stay
88
Delirium risk factors
-modifiable: benzo use, blood transfusions
-non-modifiable: increase age, dementia history, prior coma, pre-ICU emergency surgery/trauma, increase APACHE score
89
Non-pharm interventions for delirium
-re-orient the patient
-use of hearing aids or glasses
-limit noise and light at night (ear plugs etc)
-encourage natural sleep-wake cycle
-early mobilization
-family presence
-music therapy
-limit use of benzos and anticholinergic medications
90
Pharmacological options for delirium
-opioids, dexmedetomidine, melatonin receptor agonists, antipsychotics (quetiapine, haloperidol, olanzapine)
--> suggest using demedetomidine for delirium in mechanically ventilated adults where agitation is precluding weaning/extubation
91
indications of NMB
-facilitate mechanical ventilation
-minimize oxygen consumption (acute respiratory distress syndrome)
-increased muscle activity: tetany, neurolopetic malignant syndrome, anti-shivering agent
-increased intracranial pressures or intra-abdominal pressures
-surgical procedures
-rapid sequence intubation
92
neuromuscular blockers: advantages
-inhibit diaphragmatic function and reduce chest wall rigidity
-reduces oxygen consumption
-eliminates work of breathing
93
neuromuscular blockers: disadvantages
-patient CANNOT communicate
-no analgesic or sedative properties
-increase risk of DVT and skin breakdown
-corneal abrasion risk
-critical illness polyneuropathy
94
agents used in NMB
-non-depolarizing agents: cisatrasurium, rocuronium, vecuronium
-depolarizing agents: succinylcholine
95
what is cardiac arrest?
-unable to generate adequate cardiac output to support oxygen demands of tissue
-4 rhythms: ventricular fibrillation (VF), pulseless ventricular tachycardia (pVT), pulseless electrical activity (PEA), asystole
-survival depends on basic life support and or advanced cardiac life support
-immediate goal: return of spontaneous circulation
96
Cardiac arrest: CPR/treatment plan
-2 minute cycles of CPR
-end of cycle pulse and rhythm check
-understand when drug therapy is needed
-ONLY specific therapy proven to increase survival to discharge is defibrillation of VF and pulseless VT
97
what rhythm can you shock?
-VF and pulseless VT
98
VF or VT arrest steps
1- start CPR
2- shock
3- CPR 2 mins (IV access)
4- shock
5- CPR 2 mins, epinephrine every 3-5 mins, consider advanced airway capnography
7- shock
8- CPR 2 mins, amiodaraone or lidocaine, treat reversible causes
99
PEA/asystole arrest steps
*non-shockable --> epinephrine ONLY ASAP
1- epinephrine ASAP
2- CPR 2 mins, IV/IO access, epinephrine every 3-5 mins
--> if rhythm shockable: follow VF or VT arrest steps
--> if rhythm not shockable: if no signs of return of spontaneous circulation - consider appropriateness of continues resuscitation
100
Different types of medication administration
-IV
-IO: goes into the long bone and is circulated systemically
-ET (breathing tube): NAVEL- naloxone, atropine, vasopressin, epinephrine, lidocaine --> give 2 to 2.5 fold IV/IO dose down ET tube (dilute in 5-10ml sterile water or 0.9% saline
101
Epinephrine used in cardiac arrest
-helps to enhance organ perfusion by increasing arterial and aortic diastolic pressures resulting in increases in coronary and cerebral perfusion pressures
-indications: VF & pulseless VY, PEA & asystole
-administer as soon as feasible in PEA/asystole
102
Antiarrhythmics use in cardiac arrest
-no high - quality evidence to suggest that any antiarrhythmics drug given routinely during cardiac arrest increases survival to hospital discharge
-potentially normalize abnormally depolarizing and conducting myocardial cells
--> amiodarone, lidocaine, magnesium (torsades de pointes ONLY)
103
Antiarrhythmics use in cardiac arrest: Amiodarine
-indicated for VP, pulseless VT (stable VT with pulse)
-dose: VF/pulseless VT: 300mg IV bolus, may repeat 150mg IV bolus in 3-5 mins. Stable VT: 150 mg IV over 10 mins
-caution in bradycardia and hypotension
-arrhythmogenic potenial --> QT prolongation
-bolus followed by 20 ml normal saline flush
104
Antiarrhythmics use in cardiac arrest: lidocaine
-indications: VF, pulseless VT, stable VT (with pulse)
Dose: VF/pulseless VT: 1-1.5 mg/kg IV/IO, repeat 0.5-0.75 mg/kg q 5-10 mins. Stable VT: 0.5-0.75 mg/kg IV
-consider if: amiodarone unavailable, torsades de pointes due to minimal risk of QT prolongation
-with ROSC a continuous infusion of 1-4 mg/min may be initiated
105
Antiarrhythmics use in cardiac arrest: magnesium
-indicated for VF/pulseless VT, associated with torsade de pointes (wide-complex QRS)
-generally given 2 g IV bolus
-not to be used in VF/pulseless VT and normal QT internal
-flush with 10-20 ml saline
106
Reversible causes of arrest: H's (6)
-hypovolemia: loss of effective circulating volume (trauma and blood loss)
-hypoxia: lack of adequate oxygen, give 100% oxygen by mask
-hydrogen ion: severe metabolic acidosis- routine use of sodium bicarb is NOT recommended
-hypothermia
-Hyperkalemia: 1- calcium chloride or calcium gluconate. 2- sodium bicarb or insulin & dextrose
107
Reversible causes of cardiac arrest: T's (5)
-Toxins: opioids --> naloxone IV, local anesthetic toxicity --> lipid emulsion, TCAs --> sodium bicarb
-cardiac Tamponade
-Tension pneumothorax
-Thrombosis: pulmonary embolism --> alteplase (tenecteplase) or myocardial infarction --> tenecteplase, alteplase or PCI
108
deficits that are experienced after a stroke
-hemiparesis
-cognitive decline
-depression
-inability to ambulate without assistance
-PTSD
109
Ischemic stroke: risk factors
-hypertension
-cig smoking
-diabetes
-dyslipidemia
-arterial arrhythmias
-non-atrial arrhythmia cardiac conditions
-asymptotic carotid stenosis (> 60%)
-sickle cell disease
-postmenopausal hormone therapy
-oral contraceptives
-physical inactivity
-obesity
110
CHA2DS2-VASc Score
C: congestive HF or LV EEF < 40% -1
H: hypertension - 1
A: 65-74 (1), > 75 (2)
D: diabetes - 1
S: previous Stroke/TIA - 2
V: vascular disease - 1
S: female sex-1
-the higher the score the higher the need to use anticoagulants
111
Ischemic stroke: assessment/diagnosis
-time critical, accurate clinical assessment
-most important piece of information: time of symptom onset
-sudden onset of focal neurological deficit: dysphasia/dysarthria, hemianopia, weakness, ataxia, sensory loss, neglect
-symptoms are unilateral
-Primary goal: confirm the pts symptoms are due to ischemia rather than other neurological process, consider stroke mimics
--> neuro imaging: non-contrast head CT scan, MRI (more sensitive at detecting early ischemic changes)
112
Ischemic stroke mimics: neurological
-seizure/postictal state
-complicated migraine
-other intracranial process (abscess, infection, tumor, hemorrhage, MS)
-hypertensive encephalopathy
-vertigo
-cranial/peripheral neuropathies, bell's palsy
-transient global amnesia
113
Ischemic stroke mimics: metabolic
-hypoglycemia/hyperglycemia
-hyponatremia
-hepatic encephalopathy
-drug overdose
114
Ischemic stroke mimics: psychiatric
-conversion disorder
-malingering
115
Ischemic Stroke Treatment: IV fibrinolytic --> ABSOLUTE CIs
--> approved for treatment of ischemic stroke presenting within 4.5 h of symptom onset
CIS:
-< 18 y/o
-ischemic stroke within 3 months
-intracranial/intraspinal surgery within 3 months
-GI malignancy or GIB within 21 days
-LMWH within 24 hrs
-Infective endocarditis
-intra-axial intracranial neoplasm
-unclear time of onset or > 4.5 h since symptoms onset
-current intracranial hemorrhage
-severe head trauma within 3 months
-subarachnoid hemorrhage
-platelet < 100,000, INR > 1.7, aPTT > 40 sec
-DOAC within 48 hr
-aortic arch dissection
116
Ischemic Stroke Treatment: IV fibrinolytic guideline recs
-seizure at onset: thrombolytics may be administered if residual impairment are believed to be secondary to stroke
-blood glucose < 50 or > 500: if corrected, can give
-arterial puncture in the last 7 days: uncertain
-recent major trauma (14 days): if not involving the head- may be considered
-recent major surgery (14 days): may be considered
117
Ischemic Stroke Treatment: Alteplase
-activate plasminogen leads to plasmin activation which dissolves fibrin
*dose: 0.9 mg/kg (max dose 90 mg)
--> bolus: 10% as IV bolus over 1 min, infusion: 90% of the total dose over 60 mins
-1/2 life: 5 mins
118
Ischemic Stroke Treatment: Tebecteplase
*dose: 0.25 mg/kg (max dose 25 mg) given as IV push
-1/2 life: 20-24 mins
-15 fols increase in fibrin specificity compared to alteplase
119
IV Fibrinolytics: blood pressure control
-blood pressure is often elevated int he setting of acute ischemic stroke
--> hypertension (> 220/120) is detrimental and increases the risk of hemorrhagic conversion
--> hypotension may worsen ischemia
**if pt meets exclusion criteria and alteplase is NOT given, permissive HTN is allowed: BP is NOT treated unless its > 220/110 in an effort to perfuse the injured brain
120
IV Fibrinolytics: BP required for thrombolytics bolus
< 185/110
121
IV Fibrinolytics: BP required for thrombolytics infusion
< 180/105
122
Blood pressure control in acute ischemic stroke
1st line: labetalol, nicardipine
2nd line: hydralazine, enalaprilat, celvidipine
123
Fibrinolytics complications: symptomatic ICH
step 1: d/c the alteplase infusion
step 2: cryoprecipitate 10 U infused over 10-30 mins (contains fibrinogen: increases fibrinogen level by 30-60 mg/dL
step 3: anti-fibrinolytics: displace plasminogen from fibrin which inhibits fibrinolysis: tranexamic acid 1000 mg IV
124
Fibrinolytics Complications: Angieodema
-rare by potentially life threatening (5% of pts), use of ACEi is a major risk factor
step 1: maintain airway
step 2: hold ACEi
step 3: treat with these options: methylprednisolone 80-100mg IV, diphenhydramine 50 mg IV, ranitidine 50 mg IV or famotidine 20 mg IV, epinephrine 0.3 mL
125
when is thrombectomy used?
for large vessel occlusions +/- intra-arterial thrombolytics
126
Post-fibrinolytic care
-neurologic and blood pressure monitoring for 24 hrs
-dysphagia and aspiration risk
-high dose statin in all pts
-antiplatelets (aspirin for all patients, dual-antiplatelets for low NIH stroke x 21 days OR those with intracerebral stent placement
-DVT prophylaxis ( > 24 h post alteplase)
-anticoagulation (if cardioembolic stroke or hx of atrial fib)
127
secondary stroke prevention
-lifestyle and nutrition
-smoking cessation
-limited alcohol consumption
-counsel on substance abuse
-hypertension
-dyslipidemia
-diabetes
128
reasons for a provoked seizure
-intoxication
-withdrawal (ETOH, benzos)
-trauma
-meningitis
-psychiatric
-metabolic derangements
-noncompliance with seizure medications
129
reasons for unprovoked seizures
-more difficult to determine cause
-may or may not need treatment with anti epileptic medications
--> true unprovoked first time seizure does not require medication therapy
130
Inhibitory and excitatory NTs:
inhibitory: GABA
Excitatory: glutamate, aspartate, acetylcholine
131
What agents are used to stop seizures?
Benzos: lorazepam, diazepam, midazolam
132
what agents are used to prevent more seizures from occuring?
anti-epileptics: phenytoin, fosphenytoin, leviteracetam, valproic acid
133
Benzos in seizure tx
1st line: lorazepam IV 4 mg
AEs: impaired consciousness, hypotension, respiratory depression
134
(Fos) phenytoin MAO and pk
-stabilizes neuronal membranes and decreases seizure activity by increasing efflux OR decreasing influx of Na ions across the cell membranes
LD: 20 mg/kg IV
MD: 4-6mg/kg/day
-highly protein bound
AEs: cardio, extravasation
135
Phenytoin AEs
P-450 interactions*
Hirsutism
Enlarged gums
Nystagmus
Yellow-browning of skin (hepatitis)
Osteomalacia (vit D deficiency)
Interference with folate metabolism (anemia)
Neuropathies: vertigo, ataxia, headache*
Rashes/fever/SJS*
Neutropenia, thrombocytopenia
136
Monitoring of Phenytoin
goal phenytoin level: 10-20 mcg/dl
-if seizing may target 15-25 mcg/dl
-levels > 30 are associated with seizures
-must correct level for low albumin (less than 3.5)
137
Levetiractem in seizures
-60 mg/kg IV bolun
AEs: agitation, drowsiness
138
Valproic acid in seizures
LD: 40 mg/kg, MD: 1 mg/kg IV q 8h
-goal level: 50-100 mcg/mL
AEs: drowsiness, headache, thrombocytopenia, pancreatitis, hyperammonemia
**important DDI with phenytoin (both strongly protein bound)
139
Lacosamide for seizures
-add on therapy
dose: 100-200 mg IV BID
AEs: dizziness, abnormal vision, diplopia, ataxia, ~generally well tolerated
140
Refractory SE
-if there is no response to the initial anticonvulsants, SE is considered to be refractory
--> seizures lasting > 2 hours OR
--> seizures recurring at a rate of 2 or more episodes per hour without recovery to baseline between seizures, despite treatment with conventional anti-epileptic drugs
- in general, these patients have respiratory and cardiovascular compromise and systemic complications: intubations/ventilation my be required, correct hypotension
141
Post-intubation treatment (seizures)
-a paralytic is used during intubation, therefore seizures are not going to be physcially observed
--> need to start an IV infusion of an antiepileptic such as propofol or midazolam
--> need to put the patient on a long term monitoring EEG to assess ongoing seizure activity
-at this point, patients are generally on 2 - 3 IV antiepileptics + at least 1 continuous IV infusion
142
Treatment of Refractory SE
-high dose benzo: midazolam bolus + infusion
-propofol IV infusion
-phenobarbital or pentobarbital coma
143
Phenobarbital/Phentobarnital coma
-suppresses the sensory context --> sedative hypnotic
AEs: respiratory depression - pts require inntubation, hypotension, lethargy, nystagamus, thrombocytopenia, suppress immune system, decreased GI motility
144
Goals of therapy for status epilepticus
-to attain burst suppression on the LTM
-generally burst suppression is maintained for 24-48 h
-after this time period, the IV infusions are slowly titrated off while monitoring the LTM for return of seizures
145
Super Refractory status epilepticus
-ketamine infusion
LD: 1.5-3 mg/kg IV once
MD: o.1-4 mg/kg/hr
146
After burst suppression is attained in seizure - now what?
-slowly ween the IV infusions based on the LTM reading
-usually wean agents that are causing adverse reactions or need for other interventions
-if LTM demonstrates seizure activity, agents doses are increased again
147
Define shock
-a potentially fatal physiologic reaction resulting from various conditions including infection, injury, hemorrhage, dehydration, heart failure
--> hypotension (SBP < 90 OR decrease by 40 from baseline BP)
-characterized by "cellular dysoxia" : diminished blood circulation, inadequate oxygen delivery to the tissues, results in anaerobic metabolism
Outcomes = multi-organ system failure & death
148
Clinical presentation of shock: cardiovascular organ compromise
-cardiac index < 2.2
-SBP < 90
-MAP < 65
149
Clinical presentation of shock: signs of tissue hypoperfusion
-cold. clammy, mottled skin
-lactate > 2
-SCVO2 < 65%
-SVO2 < 60%
150
clinical presentation of shock: signs of organ dysfunction
-encephalopathy, lethargy, confusion
-urine output < 0.5 ml/kg/hr
-liver dysfunction
151
equation for mean arterial pressure (MAP)*
1/3 SBP + 2/3 DBP
152
what are the goals for shock management?
-determine etiology (hypovolemic, cariogenic, distributive, obstructive)
-maintain adequate tissue perfusion
-restore mean arterial pressure: MAP > 65
-normalize lactate: < 2
153
Central venous catheter
measures: central venous oxygen saturation from venous blood gas
-can be used to administer fluids, antimicrobials, parenteral nutrition
154
Pulmonary artery catheter
measures: pulmonary capillary wedge pressure (preload), cardiac output/cardiac index, mixed venous oxygen saturation & systemic vascular resistance
--> no commonly used- several complications
155
arterial line
measures: mean arterial pressure, SBP and DBP, arterial blood gas
156
What are shock goals?
-hemodynamic optimization: MAP > 65
-maintain oxygen delivery
-reversal of oxygen dysfunction
-maintain urine output: > 0.5 ml/kg/hr
-reverse encephalopathy
157
Hypovolemic Shock- causes
-inappropriately low and sudden loss of intravascular volume
Causes: hemorrhage, GI loss, severe dehydration, 3rd spacing, burns
--> #1 cause of death in those under 45: trauma and hemorrhagic shock
158
Hypovolemic shock effects on the circulatory system
-decrease preload
-decrease cardiac output
-increase after load
-decrease tissue perfusion
159
hypovolemic shock management
-identify source of loss: surgical hemostasis may be required
--> hemorrhage: REPLACE BLOOD, packed red blood cells, may also need to give fresh frozen plasma and platelets
-anticoagulation reversal (DOACS)
-GI losses, burnd, 3rd spacing : give fluids (crystalloids)
160
Cardiogenic Shock
*failure of left ventricle* to deliver blood due to impaired stroke volume or HR, associated with cardiovascular disease
Causes: *acute MI*, arrhythmias, end-stage heart failure, valve failure, valve disease, dilated cardiomyopathy etc
161
Cardiogenic shock effect on the circulatory system
-failure of emptying left ventricle = increase preload
-decreased cardiac output
-decreased tissue perfusion
-*compensatory increase in afterload*
162
Cardiogenic shock management
-MI: revascularization: cardiac catheterization or coronary artery bypass grafting
-Arrhythmias: try to achieve sinus rhythm, heart dependent on perfusion goals
-Advanced methods: left ventricular assist devices, extracorporeal membrane oxygenation
163
Distributive shock
-characterized by pronounced vasodilation
*septic shock is classic*
other causes: anaphylaxis, neurologic, myxedema coma, adrenal and hepatic insufficiency
164
Distributive shock effect on circulatory system
-*vasodilation* =decreased afterload
-decreased preload (less volume returning to the heart)
- increased then decreased cardiac function and tissue perfusion
165
Obstructive Shock
-results from critical decrease in LV stroke volume or increase in left ventricle outflow obstruction
-common etiologies: pulmonary embolism, severe pulmonary hypertension, tension pneumothorax, pericardial tamponade
166
Obstructive shock effects on cardio system
*see a decrease in LV stroke volume*
-causes decrease cardiac out put and tissue perfusion
-preload will appear elevated due to the "obstruction"
-increase in afterload in attempt to compensate
167
Shock Pharmacotherapy: fluid therapy
-fluid challenge: generally with sepsis
--> *crystalloid 30 ml/kg over 15-30 mins then by 10,l/kg boluses
168
static variables
measure of current state of hemodynamic system
169
dynamic variables
measures responsiveness of cardiovascular system to therapy
170
Shock Pharmacotherapy: steps for treatment
*initiation of vasoactive agents when MAP remains < 65 mmHg despite fluid administration*
-arterial line should be placed if possible
171
Shock Pharmacotherapy: Norepinephrine
-potent *alpha adrenergic agonist* --> increases MAP via peripheral vasoconstriction, also has beta 1 properties
-use over dopamine in septic shock
-improved renal blood flow in fluid resuscitated pts
-significant SE: vasoconstriction
172
Shock Pharmacotherapy: Epinephrine
-low dose = beta 1, increases HR and stroke volume
-high dose = increased alpha 1, vasoconstriction
-3rd in line after NE and vasopressors
-my increase "aerobic lactate production* by stimulation of B2 skeletal muscle receptors
AEs: tachycardia, arrhythmias, cardiac ischemia, peripheral vasoconstriction, reduced renal blood flow, hyperglycemia and hypokalemia
-useful for anaphylactic shock
173
Shock Pharmacotherapy: dopamine
-*dose-dependent* pharmacology
--> < 5: vasodilation
--> 5-10: increase cardiac contractility, HR
--> > 10: vasoconstriction
-most effective in *hypotensive pts with depressed cardiac function* or cardiac reserve
-utilize when low risk for arrhythmia or with significant bradycardia
AEs: tachycardia, arrhythmogenesis, peripheral vasoconstriction at high doses
174
Shock Pharmacotherapy: Phenylephrine
-selective alpha-1 adrenergic agonist: peripheral vasoconstriction, purported reflex bradycardia
-not rec in septic shock unless:
--> NE produces significant tacharrhythmias
-->cardiac output is high and BP is persistently low
--> salvage therapy when standard therapies are ineffective
AEs: severe vasoconstriction, bradycardia, myocardial ischemia
175
Shock Pharmacotherapy: dobutamine
-considered an iontrope
-produces ionotropic action via beta 1
-added to treatment of shock when cardiac output or Sv)2/ScvO2 goals have not been achieved with vasopressor therapy --> often used for cardiogenic shock
176
Shock Pharmacotherapy: Vasopressin
V1: directly constricts smooth muscles
V2: ADH activity
V3: increase ACTH activity
-sepsis dose = 0.03 units/min
GOAL = reduce concurrent vasopressor doses - should not be used as the sole vasopressor in spesis
AEs: cardiac and mesenteric ischemia
177
Shock Pharmacotherapy: Angiotension II (Giapreza)
-indicated for tx of septic shock
-produces vasoconstriction and aldosterone release
-administered by continuous infusion via central line
-add to standard therapy
AEs: *risk for thromboembolism*
178
*shock: treatment goals
-hemodynamic goals: MAP > 65, HR < 100
-renal perfusion: urine output > 0.5 ml/kg/hr
-oxygen deficiency: lactate normalized to < 2 mmol/L
-brain perfusion: improved mental status
179
examples of cardiogenic shock
-myocardial infarction
-heart failure
-cardiac arrhythmias
180
examples of hypovolemic shock
-hemorrhagic
-dehydration
181
examples of distributive shock
-SEPSIS
-anaphylaxis
-neurogenic
-pancreatitis
182
examples of obstructive shock
-cardiac tamponade
-pulmonary embolism
-tension pneumothorax
183
ways to treat cardiogenic shock
- myocardial infarction: revascularization --> cardiac catheterization or coronary artery bypass grafting (CABG)
-arrhythmias: try to achieve sinus rhythm
184
Sepsis
-life threatening organ dysfunction caused by a dysregulated host response to infection
-clinically organ dysfunction can be recognized by using the SOFA
185
Septic Shock
-subset of sepsis with profound circulatory, cellular and metabolic abnormalities
--> requires vasopressors for MAP > 65 with serum lactate > 2 mmol/L in the absence of hypovolemia
186
qSOFA rapid bedside score
at least 2 of the following:
-SBP < 100
-RR > 22
-altered mental state
187
SIRS Criteria for SS*
at least 2 of the following:
-temp > 38 or < 36
-HR > 90
-RR > 20
-WBC > 12 x 10^9 or < 4 x 10^9
188
Antibiotic use in septic shock
-blood cultures should be drawn prior to antibiotic therapy initiation as long as this does not delay initiation of abx
-delay in abx in sepsis is associated with increased mortality
-harms of unnecessary antimicrobials: allergic reactions, kidney injury, thrombocytopenia, C diff and antimicrobial resistance
-empiric therapy should be narrowed once pathogen identification and sensitivities are established and/or clinical improvement is noted --> source control is ESSENTIAL
189
abx use: sepsis is definite or probable: shock is present or shock is absent
administer abx IMMEDIATELY, ideally within 1 hr of recognition
190
abx use: sepsis is possible & shock is present
administer abx IMMEDIATELY, ideally within 1 hr of recognition
191
abx use: sepsis is possible but shock is absent
-rapid assessment of infections vs noninfectious causes of acute illness
-administer abx within 3 hours if concern for infection persists
192
pt risk factors for high risk of MRSA infections
-prior hx of MRSA infection or colonization
-recent IV abx use
-hx of recurrent skin infections or chronic wounds
-presence of invasive devices
-hemodialysis
-recent hospital admissions
-severity of illness
193
patient risk factors for multi-drug resistant organisms (needing 2 gram - agents for empiric coverage)
-proven infection of colonization with resistant organisms within the preceding year
-recent broad spectrum IV antibiotic use within previous 90 day
-travel to highly endemic country within previous 90 days
-local prevalence of antibiotic resistant organisms
-hospital acquired infections
194
Fluid therapy in septic shock
-Crystalloid 30 ml/kg over 15-30 mins, followed by 10 mL/kg boluses as needed
-should be guided by hemodynamic parameters and assessment of volume status
195
Difference colloids that can be used in septic shock
-albumin: 5%: used for fluid resuscitation, 25% used for fluid mobilization
-starches: NOT recommended for resuscitations in septic shock --> increased risk of mortality, AKI and bleeding
-blood products: if Hgb < 7 mg/dL & active bleeding
196
Pharmacotherapy of shock
-initiation of vasoactive agents when MAP remains < 65 despite fluid administration
-arterial line should be placed if possible (more accurate blood pressure monitoring)
-central venous catheter generally required for administration
197
Vasopressors in Septic Shock (top 4)
1) norepinephrine: rec as the 1st choice vasopressor
2) vasopressin: can be added if pt has inadequate MAP while on NE; shown to help reduce NE req
3) epinephrine: can be added if blood pressure goals not achieves with NE and vasopressin
4) dopamine: has increased risk of tachyarrhythmias and is generally inferior to NE as a first line vasopressor, limited utility in septic shock
198
Vasopressors in septic shock (others)
-dobutamine: added to tx of shock when pts require cardiac output support, often used for cardiogenic shock (pump failure)
-angiotensin II: reserved for refractory distributive shock
-phenylephrine: used in clinical practice when tachycardia limits NE utility
199
Hydrocorticortisone (+ fludrocortisone) in septic shock
-cortisol improved the physiologic response to sepsis
-added after poor response to fluids and vasopressors (aka refractory shock)
--> hydrocortisone 50 mg q6h IV
--> fludrocortisone 50 mcg PO daily
-recommend in septic shock when there is ongoing need for vasopressors --> usually added when patient is hypotensive despite increasing NE dose and/or initiation of vasopressin
